Literature DB >> 1500092

Defect in generation of LAK cell activity under oxygen-limited conditions.

S Ishizaka1, M Kimoto, T Tsujii.   

Abstract

In general, the in vitro induction of lymphokine activated killer (LAK) cell activities by interleukin 2 (IL-2) in human peripheral blood mononuclear cells (PMNC) has been performed in an atmosphere of 5% CO2 in air (20% O2), whereas IL-2-induced LAK cell activities are considerably reduced under concentrations of 5% O2 equal to arterial blood oxygen tension (100 mmHg) and 2% O2 equal to venous blood oxygen tension (40 mmHg). Cultured cell viability, IL-2 receptor-beta expression on large granular lymphocytes (LGL), the percentage of IL-2 receptor-beta positive LGLs and cell proliferation were not affected by oxygen-limited conditions. LAK cells were induced by IL-2 over 5 days at 20% O2, at which time the LAK cells were further stimulated by IL-2 in 2% O2 and 20% O2. Under these conditions the activity of LAK cells in 2% O2 decreased day by day, while that of LAK cells induced in 20% O2 was maintained at least until day 10 of the original culture. LAK effector cell-mediated lysis was not influenced by oxygen-limited conditions. These results point to more successful applications of the combination of oxygen therapy and adoptive cellular immunotherapy in the clinic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500092     DOI: 10.1016/0165-2478(92)90052-p

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

Review 1.  Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry.

Authors:  Elena Andreucci; Silvia Peppicelli; Jessica Ruzzolini; Francesca Bianchini; Lido Calorini
Journal:  Cancer Metastasis Rev       Date:  2022-10-13       Impact factor: 9.237

2.  Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours.

Authors:  D J Chaplin; S A Hill
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.